The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.
Saved in:
| Title: | The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer. |
|---|---|
| Authors: | Atas E; Department of Pathology, Medical University of Vienna, Vienna, Austria. emine.atas@meduniwien.ac.at.; Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, Vienna, Austria. emine.atas@meduniwien.ac.at.; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. emine.atas@meduniwien.ac.at., Berchtold K; University of Vienna, Vienna, Austria., Schlederer M; Department of Pathology, Medical University of Vienna, Vienna, Austria., Prodinger S; University of Vienna, Vienna, Austria., Sternberg F; Department of Biological Sciences and Pathobiology, Unit of Physiology and Biophysics, University of Veterinary Medicine, Vienna, Austria.; Department of Nutritional Science, University of Vienna, Vienna, Austria., Pucci P; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK., Steel C; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK., Matthews JD; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK., James ER; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK., Philippe C; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria., Trachtová K; Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, Vienna, Austria.; Central European Institute of Technology, Masaryk University, Brno, 62500, Czech Republic., Moazzami AA; Department of Molecular Sciences, Swedish University of Agricultural Sciences, 75007, Uppsala, Sweden., Artamonova N; Department of Urology, Medical University of Innsbruck, Innsbruck, Austria., Melchior F; Department of Urology, Medical University of Innsbruck, Innsbruck, Austria., Redmer T; Unit of Laboratory Animal Pathology, Institute of Pathology, University of Veterinary Medicine Vienna, Vienna, Austria., Timelthaler G; Center for Cancer Research, Medical University of Vienna, Vienna, Austria., Pohl EE; Department of Biological Sciences and Pathobiology, Unit of Physiology and Biophysics, University of Veterinary Medicine, Vienna, Austria., Turner SD; Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK.; Faculty of Medicine, Masaryk University, Brno, Czech Republic., Heidegger I; Department of Urology, Medical University of Innsbruck, Innsbruck, Austria., Krueger M; Institute for Genetics, Cologne Excellence Cluster of Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany., Resch U; Center of Physiology and Pharmacology, Department of Vascular Biology and Thrombosis Research, Medical University of Vienna, Vienna, Austria., Kenner L; Department of Pathology, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; Christian Doppler Laboratory for Applied Metabolomics (CDL-AM), Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; Unit of Laboratory Animal Pathology, Institute of Pathology, University of Veterinary Medicine Vienna, Vienna, Austria. lukas.kenner@meduniwien.ac.at.; Center for Biomarker Research in Medicine GmbH (CBmed), Graz, Austria. lukas.kenner@meduniwien.ac.at.; Department of Molecular Biology, Umeå University, Umea, Sweden. lukas.kenner@meduniwien.ac.at. |
| Source: | Molecular cancer [Mol Cancer] 2025 May 05; Vol. 24 (1), pp. 134. Date of Electronic Publication: 2025 May 05. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101147698 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-4598 (Electronic) Linking ISSN: 14764598 NLM ISO Abbreviation: Mol Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1476-4598 |
|---|---|
| DOI: | 10.1186/s12943-025-02320-y |
